A novel monoclonal antibody effective against lethal challenge with swine-lineage and 2009 pandemic H1N1 influenza viruses in mice

Authors

Hongxia Shao, Yangzhou University
Jianqiang Ye, University of Maryland
Amy L. Vincent, USDA-ARS
Nicole Edworthy, University of Maryland
Andrea Ferrero, University of Maryland
Aijian Qin, Yangzhou University
Daniel R. Perez, University of MarylandFollow

Document Type

Article

Date of this Version

2011

Citation

Virology 417 (2011) 379–384; doi:10.1016/j.virol.2011.06.021

Abstract

The HA protein of the 2009 pandemic H1N1 viruses (H1N1pdm) is antigenically closely related to the HA of classical North American swine H1N1 influenza viruses (cH1N1). Since 1998, through mutation and reassortment of HA genes from human H3N2 and H1N1 influenza viruses, swine influenza strains are undergoing substantial antigenic drift and shift. In this report we describe the development of a novel monoclonal antibody (S-OIV-3B2) that shows high hemagglutination inhibition (HI) and neutralization titers not only against H1N1pdm, but also against representatives of the α, β, and γ clusters of swine-lineage H1 influenza viruses. Mice that received a single intranasal dose of S-OIV-3B2 were protected against lethal challenge with either H1N1pdm or cH1N1 virus. These studies highlight the potential use of S-OIV-3B2 as effective intranasal prophylactic or therapeutic antiviral treatment for swine-lineage H1 influenza virus infections.